Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Biotherapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for EPHA10 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | EPHA10 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View EPHA10 Products |
| Gene Delivery | EPHA10 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. Ideal for cell-based conformation preservation. |
View EPHA10 Products |
| Benchmark Ab | Anti-EPHA10 (Sequence of Benchmark Biosimilar) Recombinant positive control for binding and internalization assays. |
View EPHA10 Products |
| Validator | EPHA10 siRNA Set For target knockdown verification and target specificity validation. |
View EPHA10 Products |
| Related Target A | EPHA2 Homologous Ephrin receptor. Crucial for off-target counter-screening and selectivity profiling. |
View EPHA2 Products |
| Related Target B | EFNA5 Ephrin ligand. Essential for ligand-blocking assays and competitive binding studies. |
View EFNA5 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, Mouse, and Cynomolgus ortholog proteins available with >95% purity and verified molecular weight. |
| Eph receptor subfamily off-target screening | Homolog panel proteins (including EPHA2, EPHA8) strictly verified by mass spectrometry to guarantee sequence identity. |
| Lack of positive control antibodies | Clinical Benchmark Antibodies (Biosimilars) engineered from published sequence patents for reference profiling. |
| False positives in cell-based screening | Sequence-verified siRNA sets included to confirm target-specific knockdowns in functional assays. |
Live EPHA10 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for EPHA10 therapeutics is intensifying, with major players shifting focus from traditional naked mAbs to Antibody-Drug Conjugates (ADCs) and CAR-T cell therapies. As an orphan receptor and pseudokinase, EPHA10 exhibits highly restricted normal tissue expression while being significantly upregulated in breast, prostate, and colon cancers. This exceptional tumor-specificity makes it an ideal target for payload-delivery modalities where off-target toxicity has historically limited clinical success. As first-generation candidates progress, the next wave of R&D is targeting optimized internalization kinetics and bispecific formats to bypass tumor escape mechanisms.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugates (ADC) | Academic Institutes, Biopharma Startups | Triple-Negative Breast Cancer (TNBC), Prostate Cancer | Internalization Assay (Requires high-purity, native glycosylated ECD-Fc fusion proteins for receptor-mediated endocytosis validation) |
| CAR-T / Cell Therapy | Oncology Biotech Developers | Solid Tumors, Colorectal Cancer | Cell Line Construction (Requires Lentiviral vectors for stable target expression to perform target cell killing assays) |
| Bispecific Antibodies | Translational Immunology Labs | Refractory Solid Tumors | Selectivity and Cross-Reactivity Panel (Requires distinct EPHA subfamily proteins to exclude off-target binding to EPHA2 or EPHA8) |